The safety tolerability, and pharmacokinetics of fosphenytoin after intramuscular and intravenous administration in neurosurgery patients

Pharmacotherapy

Volumn 16, Issue 4, 1996, Pages 638-645

  Boucher, Bradley A ^a   Feler, Claudio A ^a   Dean, J Christine ^a   Michie, David D ^a   Tipton, Benjamin K ^a   Smith Jr , Kenneth R ^a   Kramer, Ronald E ^a   Young, Byron ^a   Parks Jr , Bruce R ^a   Kugler, Alan R ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

FOSPHENYTOIN SODIUM; PHENYTOIN;

ADOLESCENT; ADULT; AGED; ARTICLE; CENTRAL NERVOUS SYSTEM DISEASE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CONVULSION; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG BLOOD LEVEL; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; GASTROINTESTINAL TOXICITY; HEMATOMA; HUMAN; INTRAMUSCULAR DRUG ADMINISTRATION; INTRAVENOUS DRUG ADMINISTRATION; LIVER TOXICITY; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NEUROSURGERY; RANDOMIZED CONTROLLED TRIAL; SKIN IRRITATION; SURGICAL PATIENT;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTICONVULSANTS; BRAIN INJURIES; DOUBLE-BLIND METHOD; FEMALE; HUMANS; INJECTIONS, INTRAMUSCULAR; INJECTIONS, INTRAVENOUS; MALE; MIDDLE AGED; PHENYTOIN; PRODRUGS;

EID: 9444232847     PISSN: 02770008     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (24)

1. Louis S, Kutt H, McDowell F. The cardiovascular changes caused by intravenous Dilantin and its solvent. Am Heart J 1967;74:523-9.
2. Dam M, Diesen V. Intramuscular administration of phenytoin. Neurology 1966;16:288-92.
3. Kostenbauder HB, Rapp RP, McGovern JP, et al. Unavailability and single-dose pharmacokinetics of intramuscular phenytoin. Clin Pharmacol Ther 1975;18: 449-56.
4. Serrano E, Roye D, Hammer R, et al. Plasma diphenylhydantoin values after oral and intramuscular administration of diphenylhydantoin. Neurology 1973;23: 311-17.
5. Earnest MP, Marx JA, Drury LR. Complications of intravenous phenytoin for the acute treatment of seizures. JAMA 1983;249:762-5.
6. Serrano EE, Wilder BJ. Intramuscular administration of diphenylhydantoin. Histologic follow up. Arch Neurol 1974;31:276-8.
7. Spengler RF, Arrowsmith JB, Kilarski DJ, et al. Severe soft-tissue injury following intravenous infusion of phenytoin. Arch Intern Med 1988;148:1329-33.
8. Bauman JL, Siepler. Phenytoin crystallization in intravenous fluids [letter]. Am J Hosp Pharm 1978;35:20-1.
9. Cloyd JC, Bosch DE, Sawchuk RJ. Concentration-time profile of phenytoin after admixture with small volumes of intravenous fluids. Am J Hosp Pharm 1978;35:45-8.
10. Newton DW, Kluza RB. Prediction of phenytoin solubility in intravenous admixtures: physiochemical theory. Am J Hosp Pharm 1980;37:1647-51.
11. Browne TR, Davoudi H, Donn KH, et al. Bioavailability of ACC-9653 (phenytoin prodrug). Epilepsia 1989;30:S27-32.
12. Andrews CO, Turnbull TL, Paloucek FP, et al. Safety and pharmacokinetics of fosphenytoin following intravenous loading dose administration [abstr]. Pharmacotherapy 1994;14:367.
13. Boucher BA, Bombassaro AM, Rasmussen SN, et al. Phenytoin prodrug 3-phosphoryloxymethyl phenytoin (ACC-9653): pharmacokinetics in patients following intravenous and intramuscular administration. J Pharm Sci 1989;78:929-32.
14. Eldon MA, Loewen GR, Voightman RE, et al. Safety, tolerance, and pharmacokinetics of intravenous fosphenytoin [abstr]. Clin Pharmacol Ther 1993;53:212.
15. Jamerson BD, Donn KH, Dukes GE, et al. Absolute bioavailability of phenytoin after 3-phosphoryloxymethyl phenytoin disodium (ACC-9643) administration in humans. Epilepsia 1990;31:592-7.
16. Gerber N, Mays DC, Donn KH, et al. Safety, tolerance and pharmacokinetics of intravenous doses of the phosphate ester of 3-hydroxymethyl-5,5-diphenylhydantoin: a new prodrug of phenytoin. J Clin Pharmacol 1988;28:1023-32.
17. Leppik IE, Boucher BA, Wilder BJ, et al. Pharmacokinetics and safety of a phenytoin prodrug given IV or IM in patients. Neurology 1990;40:456-60.
18. Wilder BJ, Ramsay E, Marriott J, et al. Safety and tolerance of intramuscular administration of fosphenytoin, a phenytoin prodrug, for 5 days in patients with epilepsy [abstr]. Neurology 1993;43(suppl 2):A308.
19. Boucher BA, Kugler AR, Hess MM, Feler CA. Pharmacokinetics of fosphenytoin, a phenytoin prodrug, following intramuscular administration in critically ill neurosurgery patients [abstr]. Crit Care Med 1995;23:A78.
20. Ramsay RE, Barkley GL, Garnett WR, et al. Safety and tolerance of intramuscular fosphenytoin (Cerebyx) in patients requiring a loading dose of phenytoin [abstr]. Neurology 1995;45(suppl 4):A249.
21. Bauer LA. Interference of oral phenytoin absorption by continuous nasogastric feedings. Neurology 1982;32:570-2.
22. Jamerson BD, Dukes GE, Brouwer KLR, et al. Venous irritation related to intravenous administration of phenytoin versus fosphenytoin. Pharmacotherapy 1994;14:47-52.
23. Baron B, Hankin S, Knapp L. Incidence of complications with intravenous administration of fosphenytoin (Cerebyx) compared with Dilantin [abstr]. Neurology 1995;45(suppl 2):A248-9.
24. Eldon MA, Loewen GR, Voightman RE, et al. Pharmacokinetics and tolerance of fosphenytoin and phenytoin administered intravenously to healthy subjects [abstr]. Can J Neurol Sci 1993;20(suppl 4):S180.